Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

[1]  H. Kitchener,et al.  Cervical cancer: A global health crisis , 2017, Cancer.

[2]  R. Angioli,et al.  Antiangiogenics and immunotherapies in cervical cancer: an update and future’s view , 2017, Medical Oncology.

[3]  A. Sasse,et al.  Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer , 2017, International Journal of Gynecologic Cancer.

[4]  M. Gore,et al.  The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  Y. Aoki,et al.  A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer , 2017, Japanese journal of clinical oncology.

[6]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[7]  亮 喜多川.  Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. , 2016 .

[8]  R. Salani,et al.  Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer. , 2016, Clinical therapeutics.

[9]  S. Ferrero,et al.  Bevacizumab for the treatment of cervical cancer , 2016, Expert opinion on biological therapy.

[10]  B. Monk,et al.  Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study , 2015, Clinical Cancer Research.

[11]  T. Schefter,et al.  Profile of bevacizumab and its potential in the treatment of cervical cancer , 2015, OncoTargets and therapy.

[12]  C. West,et al.  Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial , 2015, The Lancet. Oncology.

[13]  A. Gadducci,et al.  Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. , 2015, Critical reviews in oncology/hematology.

[14]  Jiaru Bai,et al.  A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. , 2015, Gynecologic oncology.

[15]  K. Tewari,et al.  Anti-angiogenesis therapy in gynecologic malignancies. , 2015, Oncology.

[16]  A. Dueñas-González,et al.  Emerging drugs for the treatment of cervical cancer , 2015, Expert opinion on emerging drugs.

[17]  Kathleen R. Cho,et al.  Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines , 2015 .

[18]  L. Elit,et al.  Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. , 2015, Current oncology.

[19]  B. Monk,et al.  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). , 2015, The Lancet. Oncology.

[20]  P. LoRusso,et al.  Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. , 2015 .

[21]  R Kevin Reynolds,et al.  Cervical Cancer, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  E. Kohn,et al.  State of the science in cervical cancer: Where we are today and where we need to go , 2014, Cancer.

[23]  M. Parmar,et al.  Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. , 2014 .

[24]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[25]  Xia-Wei Wei,et al.  Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment , 2013, Expert opinion on investigational drugs.

[26]  A. Sood,et al.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. , 2012, Current pharmaceutical design.

[27]  J. Bodily,et al.  Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. , 2011, Cancer research.

[28]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[29]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Monk,et al.  Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. , 2010, Gynecologic oncology.

[31]  J. Thigpen.  Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009 .

[32]  B. Monk,et al.  Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Mukhopadhyay,et al.  Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner , 2000, Oncogene.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[35]  C. Verschraegen,et al.  Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. , 1998, The New England journal of medicine.

[36]  A. Kaider,et al.  Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. , 1998, American journal of obstetrics and gynecology.

[37]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[38]  R. Mattingly,et al.  Angiogenesis of cervical neoplasia. , 1975, American journal of obstetrics and gynecology.